Osteoprotegerin, C- Reactive protein and Fibroblast Growth Factor-23 in Stage (II-IV) CKD Patients and Their potential for Increased incidence of Cardiovascular Disorders

Abstract

CKD is a public health problem and many studies had support the link between kidney dysfunction and

cardiovascular risk. Whilst, Osteoprotegerin (OPG), after its capacity to protect bone , also serum OPG in

patients with chronic kidney disease (CKD could predict the deterioration of kidney function, cardiovascular,

vascular events and all-cause mortality. On the other hand, fibroblast growth factors (FGFs), in patients

with CKD, seem to increase progressively as kidney function worsens. Furthermore, renal insufficiency

was independently associated with an increased level of C-reactive protein (CRP), which indicates a vital

pathway mediating the increased cardiovascular risk in those patients.

Our aim is to study the correlations between Osteoprotegerin, CRP and fibroblast growth factor-23 serum

levels in patients with chronic kidney disease stage (II-IV) and its possible relation with cardiovascular

events.

The study enrolled fifty-nine patients with chronic kidney disease and according to CKD-EPI Creatinine/ 2009

equation were allocated as stage (II-IV), those patients were divided into three groups: Group1 (29 patients)

with chronic kidney disease stage (II-IV) with cardiovascular events.Group2 (30 patients) with chronic

kidney disease stage (II-IV) without cardiovascular event, to be compared with Group 3 (23 apparently

healthy subjects .Serum obtained from their blood specimens to estimate; glucose, urea, creatinine, calcium,

phosphate, sodium, potassium, aldosterone, FGF-23, Osteoprotergen& C-reactive protein.

Data analysis shows that OPG levels is significantly higher in patients at stage III from that of controls ,as

well as from those in stage IV-CKD patients,While CRP levels were significantly elevated in stage III CKD

patients with values by about 300% greater than that of controls